Celgene Expected To Rake In $15B This Year With Strength Of Its Blockbuster Cancer Drug

But the company is on the look-out for its next blockbuster as Revlimid will face market competition in coming years. Meanwhile, advocate groups ask for insurance commissioners will investigate the growing use of copay accumulators.

from Kaiser Health News https://ift.tt/2LMjnfM